Previous close | 135.42 |
Open | 135.00 |
Bid | 134.06 x 800 |
Ask | 139.47 x 800 |
Day's range | 134.05 - 135.99 |
52-week range | 119.59 - 145.58 |
Volume | |
Avg. volume | 1,053,914 |
Market cap | 14.915B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | 18.07 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.00 (2.22%) |
Ex-dividend date | 05 Apr 2024 |
1y target est | N/A |
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2024.
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.